ALPS Advisors’s Ovid Therapeutics OVID Stock Holding History

ALPS Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-24,229	Closed	-$208K	–	873
2017 Q3	$208K	Buy	24,229 +2,023	+9%	+$16.8K	﹤0.01%	759
2017 Q2	$233K	Buy	+22,206	New	+$290K	﹤0.01%	738

Other funds holding OVID

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ALPS Advisors's OVID Position: Q4 2017 in Review

ALPS Advisors sold out of Ovid Therapeutics (OVID) in Q4 2017, closing a stake of 24,229 shares — an estimated $208K sold.

ALPS Advisors first reported a position in OVID in Q2 2017 and held it in 2 quarters. The position peaked at $233K in Q2 2017. 49 funds tracked by Wall St. Rank hold OVID as of Q4 2017.

ALPS Advisors reported no remaining Ovid Therapeutics position as of Q4 2017 after selling out during the quarter.
ALPS Advisors sold 24,229 Ovid Therapeutics shares in Q4 2017, an estimated $208K.
ALPS Advisors first reported a position in Ovid Therapeutics in Q2 2017 and held it in 2 quarters.
ALPS Advisors's Ovid Therapeutics position peaked at $233K in Q2 2017.
49 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.